Core Insights - Revelation Biosciences, Inc. has successfully submitted and received acceptance for the end-of-phase 1 meeting package to the FDA [1] - The company is on track to hold the meeting later this year, which aims to gather agency feedback on the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI) [1] Company Developments - The primary focus of the meeting with the FDA is to establish feedback regarding the clinical development of Gemini [1] - The company is positioned as a clinical-stage life sciences entity concentrating on rebalancing inflammation [1]

Core Insights - Revelation Biosciences, Inc. is focused on rebalancing inflammation and has made significant progress in its Phase 1b PRIME clinical study for stage 3 and 4 chronic kidney disease (CKD) patients [1] - The primary endpoint of the study, which evaluates the safety and tolerability of escalating doses of Gemini, has been successfully met [1] - The company is set to host a corporate update webcast/conference call to discuss the groundbreaking activity data from the clinical study [1] Company Overview - Revelation Biosciences, Inc. is a clinical-stage life sciences company [1] - The company aims to potentially revolutionize the treatment of acute and chronic inflammatory diseases through its innovative approach [1] Clinical Study Details - The Phase 1b PRIME clinical study focuses on patients with stage 3 and 4 CKD [1] - The study's results indicate a normalization of the inflammatory response at the cellular level in these patients [1]